Completion of Injections for China VM202 Phase I Trial
SEOUL, KOREA, June 9 – ViroMed Co., Ltd. (KOSDAQ: 084990) today announced that the final injections for patients enrolled in a Phase I clinical trial in China for VM202, the company’s proprietary DNA medicine for various types of cardiovascular disease (CVD), have been completed.
The clinical trial, which consists of 21 patients being treated with VM202-PAD, a form of VM202 for the treatment of peripheral artery disease (PAD), had been ongoing at Xuanwu Hospital, Capital University of Medical Sciences in Beijing. The Phase I trial will officially be completed once the final safety and efficacy results have been submitted to the State Food and Drug Administration (SFDA), after a three month observation period following the final injections.
Most significantly, all patient injections for the trial were completed in a mere six months, a full six months ahead of schedule. This reflects both the company’s robust clinical trial prowess, along with a growing demand for the commercial development of VM202 in China. "There has been a tremendous response and expectancy from doctors and patients in China for VM202 generated by this clinical trial," said Xu Songshan, president of Beijing Northland Biotech, the Chinese company co-sponsoring the clinical trial.
Due to rapid westernization and an unbalanced diet, lack of exercise, and heavy smoking, the number of Chinese with CVD was 30 million in 2004, with more than 2 million dying from the disease every year (Chinese Academy of Science, 2004). The target therapeutic market in China is projected to be worth US$ 112 million in 2010 and US$ 208 million in 2015 (Jain PharmaBiotech, 2006). ViroMed’s VM202 is an innovative therapeutic designed to fundamentally treat CVD and is expected to occupy a large share of the Chinese market.